GHRS - GH Research PLC
IEX Last Trade
7.175
-0.025 -0.348%
Share volume: 1,903
Last Updated: Fri 27 Dec 2024 05:28:38 PM CET
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology) :
0.45%
PREVIOUS CLOSE
CHG
CHG%
$7.20
-0.03
-0.35%
Fundamental analysis
4%
Profitability
0%
Dept financing
0%
Liquidity
0%
Performance
10%
Performance
5 Days
1.29%
1 Month
-22.09%
3 Months
1.29%
6 Months
-38.13%
1 Year
28.91%
2 Year
-27.28%
Key data
Stock price
$7.18
DAY RANGE
$7.20 - $7.26
52 WEEK RANGE
$5.47 - $14.99
52 WEEK CHANGE
$27.98
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Theis Terwey
Region: US
Website: ghres.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: ghres.com
Employees: 10
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector: Professional, Scientific, and Technical Services
GH Research PLC was incorporated in 2018 and is based in Dublin, Ireland. The company focuses on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD)
Recent news